Timothy G. Call

11.3k total citations
221 papers, 5.8k citations indexed

About

Timothy G. Call is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Timothy G. Call has authored 221 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Genetics, 128 papers in Pathology and Forensic Medicine and 74 papers in Immunology. Recurrent topics in Timothy G. Call's work include Chronic Lymphocytic Leukemia Research (190 papers), Lymphoma Diagnosis and Treatment (122 papers) and Immunodeficiency and Autoimmune Disorders (65 papers). Timothy G. Call is often cited by papers focused on Chronic Lymphocytic Leukemia Research (190 papers), Lymphoma Diagnosis and Treatment (122 papers) and Immunodeficiency and Autoimmune Disorders (65 papers). Timothy G. Call collaborates with scholars based in United States, Belarus and Israel. Timothy G. Call's co-authors include Neil E. Kay, Tait D. Shanafelt, Clive S. Zent, Susan L. Slager, Susan M. Schwager, Diane F. Jelinek, Deborah A. Bowen, Curtis A. Hanson, Kari G. Rabe and James R. Cerhan and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and Blood.

In The Last Decade

Timothy G. Call

213 papers receiving 5.7k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Timothy G. Call	4.0k	3.4k	2.2k	1.1k	862	221	5.8k
Clive S. Zent	3.5k 0.9×	2.9k 0.9×	2.2k 1.0×	881 0.8×	826 1.0×	192	5.3k
Chris Fegan	2.7k 0.7×	1.9k 0.6×	2.0k 0.9×	1.5k 1.3×	1.4k 1.6×	161	6.2k
Xavier Troussard	2.0k 0.5×	1.9k 0.6×	991 0.5×	1.3k 1.2×	1.1k 1.3×	244	4.6k
Anders Österborg	2.7k 0.7×	2.5k 0.7×	3.2k 1.4×	2.2k 2.1×	2.1k 2.5×	204	7.5k
Carsten Utoft Niemann	2.2k 0.5×	1.8k 0.5×	1.1k 0.5×	839 0.8×	520 0.6×	154	3.6k
Grzegorz S. Nowakowski	1.6k 0.4×	3.3k 1.0×	1.2k 0.5×	3.4k 3.1×	775 0.9×	346	6.3k
Fritz Offner	2.0k 0.5×	2.7k 0.8×	1.1k 0.5×	2.3k 2.1×	784 0.9×	236	6.1k
Antonio Martı́nez	1.2k 0.3×	2.9k 0.9×	1.4k 0.6×	2.8k 2.6×	423 0.5×	157	6.7k
Geir E. Tjønnfjord	1.6k 0.4×	989 0.3×	1.4k 0.7×	680 0.6×	2.9k 3.4×	217	5.7k
W. Hunstein	1.5k 0.4×	1.3k 0.4×	1.4k 0.6×	1.9k 1.7×	1.9k 2.2×	194	5.2k

Countries citing papers authored by Timothy G. Call

Since Specialization

Citations

This map shows the geographic impact of Timothy G. Call's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothy G. Call with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothy G. Call more than expected).

Fields of papers citing papers by Timothy G. Call

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothy G. Call. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothy G. Call. The network helps show where Timothy G. Call may publish in the future.

Co-authorship network of co-authors of Timothy G. Call

This figure shows the co-authorship network connecting the top 25 collaborators of Timothy G. Call. A scholar is included among the top collaborators of Timothy G. Call based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothy G. Call. Timothy G. Call is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kay, Neil E., Sameer A. Parikh, Kari G. Rabe, et al.. (2022). Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leukemia & lymphoma. 64(2). 300–311. 2 indexed citations

Boddicker, Nicholas, Sara J. Achenbach, Sameer A. Parikh, et al.. (2022). Associations of history of vaccination and hospitalization due to infection with risk of monoclonal B-cell lymphocytosis. Leukemia. 36(5). 1404–1407. 3 indexed citations

Slager, Susan L., Sameer A. Parikh, Sara J. Achenbach, et al.. (2022). Progression and survival of MBL: a screening study of 10 139 individuals. Blood. 140(15). 1702–1709. 13 indexed citations

Soof, Camilia, Tanya M. Spektor, Sameer A. Parikh, et al.. (2022). Serum B-Cell maturation antigen is an independent prognostic marker in previously untreated chronic lymphocytic leukemia. Experimental Hematology. 111. 32–40. 4 indexed citations

Liebow, Mark, Melissa C. Larson, Carrie A. Thompson, et al.. (2021). Aspirin and other nonsteroidal anti‐inflammatory drugs, statins and risk of non‐Hodgkin lymphoma. International Journal of Cancer. 149(3). 535–545. 7 indexed citations

Parikh, Sameer A., Kari G. Rabe, Neil E. Kay, et al.. (2021). The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 138(2). 149–159. 23 indexed citations

Hampel, Paul J., Timothy G. Call, Wei Ding, et al.. (2020). Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib. Blood Advances. 4(18). 4508–4511. 13 indexed citations

Parikh, Sameer A., Sara J. Achenbach, Timothy G. Call, et al.. (2020). The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Medicine. 9(10). 3390–3399. 39 indexed citations

Famà, Angelo, Melissa C. Larson, Brian K. Link, et al.. (2019). Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. Clinical Infectious Diseases. 71(5). 1221–1228. 22 indexed citations

10.

Hsieh, Ronan W., Aishwarya Ravindran, C. Christopher Hook, et al.. (2019). Etiologies of Extreme Thrombocytosis: A Contemporary Series. Mayo Clinic Proceedings. 94(8). 1542–1550. 10 indexed citations

11.

Famà, Angelo, Jinhua Xiang, Brian K. Link, et al.. (2018). Human Pegivirus infection and lymphoma risk and prognosis: a North American study. British Journal of Haematology. 182(5). 644–653. 20 indexed citations

12.

Solomon, Benjamin, Kari G. Chaffee, Jonathan Moreira, et al.. (2015). Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia. 30(2). 331–336. 35 indexed citations

13.

Bowen, Deborah A., Kari G. Rabe, Susan M. Schwager, et al.. (2014). Infectious lymphadenitis in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: a rare, but important, complication. Leukemia & lymphoma. 56(2). 311–314. 13 indexed citations

14.

Brewer, Jerry D., Tait D. Shanafelt, Adeel Zubair, et al.. (2014). Increased incidence and recurrence rates of nonmelanoma skin cancer in patients with non-Hodgkin lymphoma: A Rochester Epidemiology Project population-based study in Minnesota. Journal of the American Academy of Dermatology. 72(2). 302–309. 61 indexed citations

15.

Slager, Susan L., Sara J. Achenbach, Yan W. Asmann, et al.. (2013). Mapping of the IRF8 Gene Identifies a 3′UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. Cancer Epidemiology Biomarkers & Prevention. 22(3). 461–466. 12 indexed citations

16.

Charbonneau, Bridget, Helen M. O’Connor, Alice H. Wang, et al.. (2013). trans Fatty Acid Intake Is Associated with Increased Risk and n3 Fatty Acid Intake with Reduced Risk of Non-Hodgkin Lymphoma. Journal of Nutrition. 143(5). 672–681. 32 indexed citations

17.

Kelly, Jennifer L., Anne J. Novak, Zachary S. Fredericksen, et al.. (2010). Germline Variation in Apoptosis Pathway Genes and Risk of Non–Hodgkin's Lymphoma. Cancer Epidemiology Biomarkers & Prevention. 19(11). 2847–2858. 34 indexed citations

18.

Shanafelt, Tait D., Matthew T. Drake, Matthew J. Maurer, et al.. (2010). Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood. 117(5). 1492–1498. 104 indexed citations

19.

Shanafelt, Tait D., Timothy G. Call, Grzegorz S. Nowakowski, et al.. (2005). Clinical effects of oral green tea extracts in four patients with low grade B-cell malignancies. Leukemia Research. 30(6). 707–712. 71 indexed citations

20.

Mesa, Ruben A., Ayalew Tefferi, Michelle A. Elliott, et al.. (2001). A phase II trial of pirfenidone (5‐methyl‐1‐phenyl‐2‐[1H]‐pyridone), a novel anti‐fibrosing agent, in myelofibrosis with myeloid metaplasia. British Journal of Haematology. 114(1). 111–113. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact